CureVac has entered into a collaboration and pharma licensing agreement with Janssen Pharmaceuticals.

Under the pharma licensing agreement CureVac will collaborate with Crucell Holland on the development of an influenza vaccine based on CureVac's RNActive technology.

RNActive vaccines, based on CureVac's technology platform, have already demonstrated effectiveness and safety in several clinical trials.

Under the terms of the collaboration, CureVac will develop optimized RNActive vaccines based on Crucell's proprietary antigen sequences which will be tested in various models.

Additional details of the collaboration were not disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on Janssen company profile, recent partnering, M&A and financing news and articles

Report: Partnering Deals and Alliances with Johnson & Johnson / Janssen

Report: Influenza Partnering 2007-2013

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter